Sclafani, Francesco
Chau, Ian http://orcid.org/0000-0003-0286-8703
Cunningham, David
Hahne, Jens C.
Vlachogiannis, George
Eltahir, Zakaria
Lampis, Andrea
Braconi, Chiara
Kalaitzaki, Eleftheria
De Castro, David Gonzalez
Wotherspoon, Andrew
Capdevila, Jaume
Glimelius, Bengt
Tarazona, Noelia
Begum, Ruwaida
Lote, Hazel
Hulkki Wilson, Sanna
Mentrasti, Giulia
Brown, Gina
Tait, Diana
Oates, Jacqueline
Valeri, Nicola
Article History
Received: 6 June 2017
Accepted: 27 December 2017
First Online: 23 January 2018
Competing Interests
: David Cunningham received research funding from: Roche, Amgen, Celgene, Sanofi, Merck Serono, Novartis, Astra Zeneca, Bayer, Merrimack and MedImmune. Clare Peckitt has had advisory roles with Sanofi. Ian Chau has had advisory roles with Merck Serono, Roche, Sanofi Oncology, Bristol Myers Squibb, Eli-Lilly, Novartis, Gilead Science. He has received research funding from Merck-Serono, Novartis, Roche and Sanofi Oncology, and honoraria from Roche, Sanofi-Oncology, Eli-Lilly, Taiho. All other authors declare that they have no conflicts of interest.